Chavda Vivek P, Vora Lalitkumar K, Vihol Disha R
Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad - 380009, Gujarat, India.
School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, BT9 7BL, UK.
Clin Complement Med Pharmacol. 2021 Dec;1(1):100004. doi: 10.1016/j.ccmp.2021.100004. Epub 2021 Aug 9.
Various vaccine platforms are geared against COVID-19 vaccine development to produce immunogens in cells. To design a recombinant protein-based COVID-19 vaccine, Vaxine pty Ltd used computer models of the spike protein and its human receptor, ACE2, to identify how the virus infects human cells. Based on this, the COVAX-19Ⓡ vaccine is synthesized. It does reduce not only COVID-19 disease but also blocks virus shedding and transmission. Researchers are optimistic that this vaccine candidate could be clinically available soon with sufficient vaccine efficacy with a considerable amount of reduction in vaccination-related side effects.
各种疫苗平台都致力于针对新冠病毒疫苗的研发，以便在细胞中产生免疫原。为了设计一种基于重组蛋白的新冠病毒疫苗，Vaxine私人有限公司利用刺突蛋白及其人类受体ACE2的计算机模型，来确定病毒如何感染人类细胞。基于此，合成了COVAX-19Ⓡ疫苗。它不仅能减轻新冠疾病，还能阻止病毒传播。研究人员乐观地认为，这种候选疫苗可能很快就能投入临床使用，具有足够的疫苗效力，且能大幅减少疫苗相关的副作用。
